A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3

Coulie, Pierre;Karanikas, Vaios;Colau, Didier;Lurquin, Christophe;Boon-Falleur, Thierry;et.al.
(2001) Proceedings of the National academy of sciences of the United States of America — Vol. 98, n° 18, p. 10290-10295 (2001)

Files

pdfdocument.pdf
  • Restricted Access
  • Adobe PDF
  • 580.82 KB
Request a copy

Details

Authors
  • Coulie, Pierreorcid-logoUCLouvain
    Author
  • Karanikas, Vaios
    Author
  • Colau, DidierUCLouvain
    Author
  • Lurquin, Christophe
    Author
  • Boon-Falleur, ThierryUCLouvain
    Author
Show more
Abstract
Vaccination of melanoma patients with tumor-specific antigens recognized by cytolytic T lymphocytes (CTL) produces significant tumor regressions in a minority of patients. These regressions appear to occur in the absence of massive CTL responses. To detect low-level responses, we resorted to antigenic stimulation of blood lymphocyte cultures in limiting dilution conditions, followed by tetramer analysis, cloning of the tetramer-positive cells, and T-cell receptor (TCR) sequence analysis of the CTL clones that showed strict specificity for the tumor antigen. A monoclonal CTL response against a MAGE-3 antigen was observed in a melanoma patient, who showed partial rejection of a large metastasis after treatment with a vaccine containing only the tumor-specific antigenic peptide. Tetramer analysis after in vitro restimulation indicated that about 1/40,000 postimmunization CD8(+) blood lymphocytes were directed against the antigen. The same TCR was present in all of the positive microcultures. TCR evaluation carried out directly on blood lymphocytes by PCR amplification led to a similar frequency estimate after immunization, whereas the TCR was not found among 2.5 x 10(6) CD8(+) lymphocytes collected before immunization. Our results prove unambiguously that vaccines containing only a tumor-specific antigenic peptide can elicit a CTL response. Even though they provide no information about the effector mechanisms responsible for the observed reduction in tumor mass in this patient, they would suggest that low-level CTL responses can initiate tumor rejection.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Coulie, P., Karanikas, V., Colau, D., Lurquin, C., Landry, C., Marchand, M., Dorval, T., Brichard, V., & Boon-Falleur, T. (2001). A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proceedings of the National academy of sciences of the United States of America, 98(18), 10290-10295. https://doi.org/10.1073/pnas.161260098 (Original work published 2001)